Inhibition of nonhomologous end joining‐mediated <scp>DNA</scp> repair enhances <scp>anti‐HBV CRISPR</scp> therapy-Reference-Cited by-同舟云学术

Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy

Published:2022-05-24 Issue:9 Volume:6 Page:2474-2487
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Murai Kazuhiro¹^ORCID,Kodama Takahiro¹^ORCID,Hikita Hayato¹,Shimoda Akiyoshi¹,Fukuoka Makoto¹,Fukutomi Keisuke¹,Shigeno Satoshi¹,Shiode Yuto¹,Motooka Daisuke²,Higuchi Yuichiro³^ORCID,Miyakawa Kei⁴,Suemizu Hiroshi³,Ryo Akihide⁴,Tahata Yuki¹,Makino Yuki¹,Yamada Ryoko¹,Sakamori Ryotaro¹^ORCID,Tatsumi Tomohide¹,Takehara Tetsuo¹

Affiliation:

1. Department of Gastroenterology and Hepatology Osaka University Graduate School of Medicine Suita Japan

2. Genome Information Research Center Research Institute for Microbial Diseases Osaka University Suita Japan

3. Laboratory Animal Research Department Biomedical Research Laboratory Central Institute for Experimental Animals Kawasaki Japan

4. Department of Microbiology Yokohama City University School of Medicine Yokohama Japan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.2014

Reference35 articles.

1. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?

2. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats

3. AASLD guidelines for treatment of chronic hepatitis B

4. Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan

5. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome‐wide loss‐of‐function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus‐integrated hepatoma cells;Cancer Science;2024-01-29

2. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA;Viruses;2023-11-25

3. Targeting Hepatitis B Virus DNA Using Designer Gene Editors;Clinics in Liver Disease;2023-11

4. CRISPR-Cas9 genetic screen leads to the discovery of L-Moses, a KAT2B inhibitor that attenuates Tunicamycin-mediated neuronal cell death;Scientific Reports;2023-03-09

5. Gene Editing Technologies to Target HBV cccDNA;Viruses;2022-11-28